ロード中...
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
Alemtuzumab is a humanized monoclonal antibody against CD52 (cluster of differentiation 52) and is approved for the therapy of relapsing-remitting multiple sclerosis. The application of alemtuzumab leads to a rapid, but long-lasting depletion predominantly of CD52-bearing B and T cells with reprogra...
保存先:
| 出版年: | Int J Mol Sci |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4519957/ https://ncbi.nlm.nih.gov/pubmed/26204829 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms160716414 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|